Global leaders in stem cell research and regenerative medicine will be converging on Buenos Aires, Argentina Oct. 2, 3 and 4 2014 for the first ever Global Stem Cells Symposium.
GlobalStemCellsGroup.com will host the First International Symposium on Stem Cell Research in Buenos Aires, Argentina Oct. 2, 3 and 4. The symposium will provide an opportunity to showcase advancements in stem cell research and therapies on a global level and establish a dialogue among the world’s leading stem cell experts. Pioneers and luminaries in stem cell medicine will be featured speakers as well as accomplished guests prepared to share their knowledge and experience in their individual medical specialties.
Regenerative medicine as a field is still in its infancy, and Global Stem Cells Group President and CEO Benito Novas believes it is time to clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing. The first step, Novas says, is establishing a dialogue between researchers and practitioners in order to move stem cell therapies from the lab to the physician’s office.
“Our objective is to open a dialogue among the world’s medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices,” Novas says. “Our mission is to bring the benefits of stem cell therapies to the physician’s office for the benefit and convenience of the patient, safely and in full compliance with the highest standard of care the world has to offer.”
An interdisciplinary team of leading international stem cell experts will provide a full day of high-level scientific lectures aimed at medical professionals.
Among the growing list of speakers are some of the world’s most prominent authorities on stem cell medicine including:
Kristin Comella, M.A.,CEO and Chief Scientific Officer of Bioheart, Inc.
Vasilis (Bill) Paspaliaris, M.D., Director and founder of Adistem Ltd.
David B Harrell, PhD, founder and CEO Harrell Biosciences Consulting
Joseph Purita, M.D., Medical Director of the Institute of Regenerative and Molecular Orthopaedics in Boca Raton, Florida.
Todd Malan, M.D., founder of the Innovative Cosmetic Surgery Center and the Center for Regenerative Cell Medicine, Washington DC
The objective of Global Stem Cell Group’s international symposium is to educate the public and the medical community, and at the same time establish a dialog between physicians, scientists, biotech companies and regulatory agencies in order to advance stem cell technologies so they can be used to benefit people who need them.
Global Stem Cells Group is also joining forces with some of the most prestigious regenerative medicine conferences in South America including:
XVI Latin American Congress of Cosmetic and Aesthetic Surgery, Buenos Aires presided by Professor Julio Ferreira
XIX Congress of Orthopedics and Musculoskeletal Medicine, Rio de Janeiro, Brazil.
Stem cell therapies are revolutionizing the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases
For more information on the Global Stem Cell Group First International Symposium on Stem Cells and Regenerative Medicine and the event’s lineup of speakers, visit the Global Stem Cells Symposium website.

Global Stem Cells, Inc. has announced plans to establish a stem cell training course in Dehli, India, in collaboration with Revita Life Sciences of Dehli, May 22 and 23.
GlobalStemCellsGroup.com and Revita Life Sciences have announced plans to present the adipose and bone marrow stem cells course hosted by Himanshu Bansal, M.D., May 22-23 in Delhi.
Revita Life Sciences is a biotech company based in Dehli that specializes in stem cell research, training and clinical applications protocol development in regenerative medicine. Stem Cell specialists from both Global Stem Cells Group and Revita will participate in the two-day training program designed to help medical professionals bring stem cell therapies to the physicians’ office.
The adipose-derived harvesting, isolation and re-integration training course for the advancement of stem cell procedures is a two-day, hands-on intensive training course developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose (fat) tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctor’s office by teaching effective “in office“ regenerative medicine techniques.
About Revita Life Science:
Revita Life Sciences is a biotechnology company that provides complete support to patients from their first inquiry through stem cell therapy performed by a Revita Life Science specialized physician.
Revita’s primary objective is the development of stem cell therapies that target areas of significant unmet or poorly met medical need. Years of research and experience have resulted in substantial improvements in the health and condition of patients suffering from a variety of illnesses through stem cell therapy, even where other treatments have failed.
Revita Life Sciences’ skilled team of physician use fresh, biologically intact stem cells extracted directly from the patient (autologous adult stem cells) to eliminate any risk of rejection. The result is personalized stem cell therapy created especially for them.
Revita Life Sciences is carrying out research, training and clinical applications-protocol development in regenerative medicine, with emphasis on autologous adult stem and progenitor cells possessing regenerative capabilities for clinical application. For more information, visit the Revita Life Sciences website.

Global Stem Cells Group and Bioheart announce the launch of a unique clinical trial called “Adipose Derived Cells for Chronic Obstructive Pulmonary Disease.”
Global Stem Cells Group, Inc. and BioHeart, Inc. announce the launch of a clinical trial for the treatment of Chronic Obstructive Pulmonary Disease (COPD) using adipose-derived stem cell technology. The clinical trials will be held at the Global Stem Cells treatment center in Cozumel, Mexico, as well as in several U.S. states. Global Stem Cells Group affiliate Cellgenic in collaboration with CMC Hospital of Cozumel offer cutting-edge cellular medicine treatments to patients from around the world.

The study titled “An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered intravenously in Patients with Chronic Obstructive Pulmonary Disease” is lead by principal investigator Armando Pineda Velez, Global Stem Cells Group Medical Director. Global Stem Cells Group has represented that it offers the most advanced protocols and techniques in cellular medicine from around the world.

The Cozumel clinical trials will be lead by Rafael Moguel, M.D., an advocate and pioneer in the use of stem cell therapies to treat a wide variety of conditions.

COPD is one of more than 150 chronic conditions that are treatable with adult stem cells, eliminating the potential risk of surgery, transplants, and toxic drugs

Details of the protocol and eligibility criteria can be found on the government clinical trial website at: http://www.clinicaltrials.gov.

About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About Bioheart:
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.

Bioheart, Inc., in collaboration with Global Stem Cells, Inc. have initiated a new clinical site in Cozumel, Mexico.
Bioheart Inc., a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group, Inc. in Cozumel, Mexico. The two companies successfully treated their first congestive heart failure patient at the new clinical site last week, using Bioheart’s AdipoCell (adipose derived stem cells).
The therapy involved the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. The recovered stem cells were injected into the patients’ heart with Bioheart’s MyoCath® needle injection catheter which allows for introduction of the cells directly into the heart without invasive surgery.
Rafael Moguel, M.D., Head of the Cardiac Program at the Centro Medico de Cozumel, was the treating interventional cardiologist for the Bioheart therapy procedure.
“Our center is very excited to participate in the cutting edge programs at Bioheart,” Moguel says. “We can offer new hope to patients suffering from debilitating diseases by utilizing regenerative medicine, and delivering them non-invasively into the heart.”
The MyoCath catheter was introduced using a radial artery approach, the first such documented stem cell case using this delivery method. The benefit of a radial artery approach is that it does not require the patient to lie flat for up to six hours, as in a femoral artery approach. Patients are able to sit up, walk and eat immediately following the procedure, and the risk of internal bleeding is eliminated.
Bioheart and Global Stem Cells Group have designed several different protocols to be utilized at the center in Cozumel, offering treatments to patients for a variety of different indications.
About Bioheart, Inc.:
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.

Global Stem Cells Group has announced the Dominican Republic launch of Plasma Plus medical service company, providing certified professionals, top of the line equipment, and FDA approved protocols and kits for application of platelet rich plasma therapy.
The Global Stem Cells Group, Inc. has announced the launch of Plasma Plus medical services company in the Dominican Republic. Plasma Plus provides certified medical professionals, top of the line equipment, FDA approved protocols for hospitals, clinics and physicians, and protocol-specific equipment and consumables for application of platelet rich plasma therapy (PRP.)
Plasma Plus also assigns a qualified, certified health care professional to perform the PRP extraction and preparation procedures. Clients need only apply the therapy where needed to achieve the rejuvenating, regenerating and revitalizing results of PRP therapy, eliminating excess overhead costs, need for equipment purchases and preoccupation with maintaining protocol standards.
The benefits of PRP treatments extend through a wide and diverse group of medical fields, from cosmetic surgery to dentistry; Plasma Plus is committed to making PRP an available and cost-effective treatment option for medical professionals.
The company’s product line includes:
Plasma prep service solutions for the cosmetics, aesthetics and anti-aging industries.
Med Biologics- Genesis CSTM Service Solutions.
Med Biologics- Pure PRPTM Service Solutions to meet all clinical demands.
Pure PRPTM procedure packs.
Derma Roller RejuvenationTM.
Plasma MatrixTM- Autologous Fibrin Filler.
Painless PRPTM – Adilight-2TM.
Stem RejuvenationTM.
The Plasma Plus equipment line includes:
Elite SeriesTM Centrifuge by Emcyte.
PlasmaPrepTM Centrifuge by STI.
Biofiller Maker.
AdiLight-2TM by Adistem.
For more information on Plasma Plus medical services, products and equipment, visit the Plasma Plus website, email info@www.plasmaplusonline.com or call 849.943.2988.
About Plasma Plus:
Plasma Plus is an innovative, turn-key medical service company providing certified professionals, state-of-the-art equipment, and FDA approved protocols and kits for application of platelet rich plasma therapy (PRP). Plasma Plus technicians are trained and certified by a qualified team of medical professionals that includes physicians and nurses. Staffed by physicians, medical consultants and leading scientific researchers in the field to provide patients with the leading platelet rich plasma therapy.
PRP treatments utilize the body’s own resources to stimulate growth and regeneration with an overabundance of growth factors derived from platelets.
The applicability of PRP treatments extends through diverse medical fields, from dentistry to orthopedic surgery including: dentistry, maxillofacial surgery, orthopedic surgery, neurosurgery, plastic surgery, aesthetic therapies, chronic wound treatment and more.
Please visit the Plasma Plus website for more information.

Global Stem Cells Group has announced plans to attend the 21st Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Las Vegas Dec, 15th. Joseph Purita, M.D., a lead trainer for Global Stem Cells Group subsidiary Stem Cell Training, Inc. will be a featured speaker at the event.
Global Stem Cells Group, Inc. announced plans to attend 21st Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine (a4m) at the Venetian/Palazzo Hotel in Las Vegas, Dec. 15, 2013. The prestigious conference, hosted by the American Academy of Anti-aging Medicine, will be attended by physicians and medical practitioners from around the world who will discuss practice management stem cell technology, certification, personalized lifestyle medicine, aesthetic medicine, pellet therapy, brain health, case studies and. Workshops on personalized lifestyle medicine and aesthetic medicine will also be held.
Joseph Purita, M.D., a lead trainer for Stem Cell Training, Inc. and a pioneer in the use of stem cell therapies in orthopedics, will be a featured speaker at the conference. Purita joins an illustrious group of speakers including: Author Judith Reichman, M.D., women’s health care expert and specialist in gynecology, infertility and menopause; Travis Stork, M.D., ER physician and host of the Emmy Award-winning talk show, “The Doctors;” and Actress and Author Suzanne Somers, a dedicated health advocate and proponent of alternative and integrative medicine.
Global Stem Cells Group plans to promote its new postgraduate program, “Studies in Cellular Therapy and Tissue Engineering”, in partnership with Maimonides University, as well its newly formed alliance with EmCyte Corp. to promote in-office regenerative medicine solutions. Fort Myers, Florida-based EmCyte is a leading provider of biotechnology solutions in the United States, develops biological products for platelet rich plasma and bone marrow concentrate grafting procedures.
For more information on the World Congress on Anti-Aging, Regenerative and Aesthetic Medicine, visit the a4m website.

Two specialists from Stem Cell Training, Inc., a division of the Global Stem Cells Group, were invited keynote speakers at last month’s prestigious 7th annual World Meeting of the Australian Academy for Anti-Aging Medicine in Melbourne, Australia.
Joseph Purita, M.D. and Maritza Novas R.N., M.S.N., were in Melbourne August 24th and 25th for the two-day conference, focusing their discussions on stem cell medicine and its anti-aging applications. Purita and Novas joined other leaders from the world’s medical community to share cutting-edge research and techniques from multiple medical streams to present groundbreaking advances in evidence-based, best-practice protocols for the early detection, prevention and treatment of obesity, metabolic disorders, related diseases and premature decline.
Purita, a lead trainer for Stem Cell Training, Inc. and a pioneer in the use of stem cells in orthopedics, graduated from Georgetown University Medical School and has been with the Boca Raton Orthopedic Group since 1981. He is a Global Stem Cell Group Advisory Board member and a member of the following organizations:

• Fellow, American College of Surgeons
• Fellow, American Academy of Orthopedic Surgeons
• Southern Medical Association
• American Medical Association
• Broward County Medical Society
• Palm Beach Medical Society
• Florida Medical Association
• Palm Beach Orthopedic Society

Purita is Board Certified by the following organizations:

• American Board of Pain Management
• Anti-Aging Medicine
• American Board of Orthopedic Surgery
• American College of Orthopedic Surgery

Novas received her Medical Degree from the Medical School of University of Havana, completed her post-doctoral training and residency program in Family Medicine at the University of Phoenix, and is a member in good standing with the American Academy of Anti-aging medicine. She specializes in Functional Medicine, Age Management, Bio-identical Hormone Therapy, Weight Control and Rejuvenation. Novas has been a certified Adistem Specialist for more than four years.
Novas is a lead trainer with Stem Cell Training, Inc., having successfully trained and certified more than 150 physicians globally. She is also a member of Stem Cell Training, Inc.’s of research and development team, and has assisted in the development of new proprietary adipose and bone marrow protocols currently being used in the company’s comprehensive courses.

Cell Training Inc. has announced an alliance with Far Eastern University to properly train physicians to harvest and reintegrate stem cells derived from adipose tissue, bone marrow and dental pulp.
Stem Cell Training, Inc., a division of the Global Stem Cells Group, today announced a newly formed alliance with Far Eastern University in Manila, Philippines for the advancement of stem call procedures. The alliance was established to train physicians and mid-level providers in techniques for harvesting and reintegrating stem cells derived from adipose (fat) tissue, bone marrow and dental pulp.
Through the alliance, the Miami-based biotechnology training company has established a two-day, hands-on intensive training course for physicians and high level practitioners titled “Adipose Derived Harvesting, Isolation and Re-integration Training Course”, taught at the Far Eastern University School of Medicine.
Conducted by Joseph Purita, M.D., a pioneer in the use of stem cells in orthopedics and founder of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, the program covers all of the essentials necessary to perform adipose-derived stem cell protocols and bone marrow-derived stem cell harvesting, processing and activation procedures in a clinical environment. New classes are scheduled for September 24-25 and November 18-19, 2013 at Far Eastern University.
Stem Cell Training, Inc. is a multi-dimensional company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.
The company’s training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.’s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.

Stem Cell Training Inc. has announced a new joint venture with The Research Center in Tissue Engineering and Cellular Therapy at Maimonides University in Buenos Aires to launch a post-graduate diploma program in cellular therapy and tissue engineering.
Stem Cell Training, Inc., a division of the Global Stem Cells Group, announced today the launch of a post-graduate diploma program with the Research Center in Tissue Engineering and Cellular Therapy at Maimonides University in Buenos Aires. The diploma program, the first of its kind worldwide, is designed for physicians and practitioners to bridge the gap between advanced laboratory practices and the practitioner’s office.
According to Gustavo Antonio Moviglia, M.D., a lead trainer for Stem Cell Training, Inc., the decision to launch the post-graduate diploma coursework has evolved out of advances in cell biology in the late 20th and early 21st centuries which have given rise to a new form of medical therapy in which cells and tissues are used as healing elements, no longer just to supplement or replace deficient or ailing cells.
Since 2000, Maimonides University and Moviglia have worked to generate scientific and medical applications based on tissue engineering and cellular therapy, to enrich this specialty and establish their own philosophy. Their work will be the basis for the postgraduate course, aiming to create academic space for training professionals and developing new knowledge in this area of medicine.
With many in the field of medical research believing cell therapy to be the central point around which future medicine will revolve, Stem Cell Training, Inc. and Maimonides University have chosen to lead the process together, providing medical professionals with the scientific and practical methodologies of this new discipline.
For more information, visit the Diplomat Tissue Engineering page of the Stem Cell Training, Inc. website.